Selective efficacy of zoledronic acid on metastasis in a patient‐derived orthotopic xenograph (PDOX) nude‐mouse model of human pancreatic cancer. Issue 3 (14th November 2014)

• Record Type: Journal Article
• Authors: Hiroshima, Yukihiko; Maawy, Ali A.; Katz, Matthew H.G.; Fleming, Jason B.; Bouvet, Michael; Endo, Itaru; Hoffman, Robert M.
• Is Part Of: Journal of surgical oncology. Volume 111:Issue 3(2015:Mar. 01)
• Page Start: 311
• Page End: 315
• Publication Date: 2014-11-14
• Subjects: Cancer -- Surgery -- Periodicals; Neoplasms -- Periodicals; 616
• DOI: 10.1002/jso.23816
• Languages: English
• ISSNs: 0022-4790

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="jso23816-sec-0001" sec-type="section"> <title>Background and Objectives</title> <p>Patient‐derived orthotopic xenograft (PDOX) nude‐mouse models replicate the behavior of clinical cancer, including metastasis. The objective of the study was to determine the efficacy of zoledronic acid (ZA) on metastasis of a patient‐derived orthotopic xenograft (PDOX) nude‐mouse model of pancreatic cancer.</p> </sec> <sec id="jso23816-sec-0002" sec-type="section"> <title>Methods</title> <p>In the present study, we examined the efficacy of ZA on pancreatic cancer growth and metastasis in a PDOX nude‐mouse model.</p> </sec> <sec id="jso23816-sec-0003" sec-type="section"> <title>Results</title> <p>ZA monotherapy did not significantly suppress primary tumor growth. However, the primary tumor weight of gemcitabine (GEM) and combination GEM + ZA‐treated mice was significantly decreased compared to the control group (GEM: <italic>P</italic> = 0.003; GEM + ZA: <italic>P</italic> = 0.002). The primary tumor weight of GEM + ZA‐treated mice was significantly decreased compared to GEM‐treated mice (<italic>P</italic> = 0.016). The metastasis weight decreased in ZA‐ or GEM‐treated mice compared to the control group (ZA: <italic>P</italic> = 0.009; GEM: <italic>P</italic> = 0.007. No metastasis was detected in combination GEM + ZA‐treated mice compared to the control group (GEM + ZA; <italic>P</italic> = 0.005).</p> </sec> <sec id="jso23816-sec-0004" sec-type="section"> <title>Conclusions</title> <p>The results of the present study indicate that ZA can selectively target metastasis in a pancreatic cancer PDOX model and that the combination of ZA and GEM should be evaluated clinically in the near future for this highly treatment‐resistant disease. <italic>J. Surg. Oncol. 2015 111:311–315</italic>. © 2014 Wiley Periodicals, Inc.</p> </sec> </abstract>